By clicking “View Open Positions”, you acknowledge and consent to your personal information being transferred cross-border to Pivotal Headquarters in Hong Kong. For more details, please refer to the Recruitment Privacy Policy.
Pivotal·Family | Zenas与诺诚健华达成逾20亿美元自免管线授权协议,同步增发再获1.2亿美元融资
Pivotal·Family | Zenas BioPharma和Royalty Pharma达成融资协议,最高可达3亿美元
Pivotal夏季回顾 | 碧沃投资本荣登多项榜单,国际化生态持续赋能
Pivotal·Family | Windward宣布启动长效TSLP抗体药物全球 II 期哮喘临床试验
Pivotal·Family | 维昇药业与安科生物达成战略合作 共拓长效生长激素中国市场
三重焕新,启航未来——Pivotal中文品牌发布暨乔迁新址、新官网上线
Pivotal·Family | 合凯维HerResolve全球首发,无创诊断子宫内膜异位症92%准确率获LDT验证
Pivotal bioVenture柳丹博士受邀参加2025中关村论坛年会
Pivotal·Family | 祝贺港股生长发育及内分泌第一股维昇药业成功上市
Pivotal·Family | 极目生物葡萄膜炎性黄斑水肿新药锋脉®/ARCATUS®获澳大利亚新药上市批准
Pivotal bioVenture Partners China Closes Inaugural $150 Million Early Stage VC Fund
Oncologie Launches with 16.5M USD Seed Funding Led by Pivotal bioVenture Partners China
Arctic Vision Announces US$32MN in Series A
Oncologie(鼎航医药)公布最新临床研究数据
Evommune完成1250万美元种子轮融资
OncXerna is selected as Global Top 5 Precision Medicine Startups
Exscientia announces investment of up to $525M
Arctic Vision Received China IND Clearance for Phase III Study of ARVN002 to Reduce Paediatric Myopia Progression
Engrail Therapeutics Extends Series A Financing to $64 Million
QIAGEN and OncXerna Therapeutics Sign Licensing and Master Companion Diagnostic Agreements